{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T19:05:48Z","timestamp":1776366348326,"version":"3.51.2"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Topiramate is a second-generation antiepileptic drug used as monotherapy and adjunctive therapy in adults and children with partial seizures. A population pharmacokinetic (PPK) analysis was performed to improve the topiramate dosage adjustment for individualized treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients whose steady-state serum concentration of topiramate was routinely monitored at Kyoto University Hospital from April 2012 to March 2013 were included in the model-building data. A nonlinear mixed effects modeling program was used to evaluate the influence of covariates on topiramate pharmacokinetics. The obtained PPK model was evaluated by internal model validations, including goodness-of-fit plots and prediction-corrected visual predictive checks, and was externally confirmed using the validation data from January 2015 to December 2015.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 177 steady-state serum concentrations from 93 patients were used for the model-building analysis. The patients' age ranged from 2 to 68 years, and body weight ranged from 8.6 to 105 kg. The median serum concentration of topiramate was 1.7 mcg\/mL, and half of the patients received carbamazepine coadministration. Based on a one-compartment model with first order absorption and elimination, the apparent volume of distribution was 105 L\/70 kg, and the apparent clearance was allometrically related to the body weight as 2.25 L\u00b7h<jats:sup>\u22121<\/jats:sup>\u00b770 kg<jats:sup>\u22121<\/jats:sup> without carbamazepine or phenytoin. Combination treatment with carbamazepine or phenytoin increased the apparent clearance to 3.51 L\u00b7h<jats:sup>\u22121<\/jats:sup>\u00b770 kg<jats:sup>\u22121<\/jats:sup>. Goodness-of-fit plots, prediction-corrected visual predictive check, and external validation using the validation data from 43 patients confirmed an appropriateness of the final model. Simulations based on the final model showed that dosage adjustments allometrically scaling to body weight can equalize the serum concentrations in children of various ages and adults.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The PPK model, using the power scaling of body weight, effectively elucidated the topiramate serum concentration profile ranging from pediatric to adult patients. Dosage adjustments based on body weight and concomitant antiepileptic drug help obtain the dosage of topiramate necessary to reach an effective concentration in each individual.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000383","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T12:23:11Z","timestamp":1487852591000},"page":"124-131","source":"Crossref","is-referenced-by-count":9,"title":["Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data"],"prefix":"10.1097","volume":"39","author":[{"given":"Masato","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"},{"name":"Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuko","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"},{"name":"Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan;"},{"name":"Department of Pharmacy, Kobe University Hospital, Kobe; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"},{"name":"Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"},{"name":"Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Epilepsy, Movement Disorders and Physiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pharmthera.2006.07.005","article-title":"Novel anticonvulsant drugs","volume":"113","author":"Stefan","year":"2007","journal-title":"Pharmacol Ther."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2165\/00003495-200767150-00008","article-title":"Topiramate: a review of its use in the treatment of epilepsy","volume":"67","author":"Lyseng-Williamson","year":"2007","journal-title":"Drugs"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1528-1167.2005.00326.x","article-title":"Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies","volume":"46","author":"Patsalos","year":"2005","journal-title":"Epilepsia"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?","volume":"45","author":"Johannessen","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000091867.09720.6B","article-title":"Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy","volume":"61","author":"Christensen","year":"2003","journal-title":"Neurology"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/phrs.1997.0124","article-title":"A pharmacological and clinical review on topiramate, a new antiepileptic drug","volume":"35","author":"Perucca","year":"1997","journal-title":"Pharmacol Res."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/00003088-200443120-00001","article-title":"Pharmacokinetic interactions of topiramate","volume":"43","author":"Bialer","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/00007691-200312000-00008","article-title":"Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response","volume":"25","author":"Ferrari","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1248\/bpb.33.1176","article-title":"A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy","volume":"33","author":"Vovk","year":"2010","journal-title":"Biol Pharm Bull."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.eplepsyres.2010.12.004","article-title":"Topiramate pharmacokinetics in infants and young children: contribution of population analysis","volume":"93","author":"Bouillon-Pichault","year":"2011","journal-title":"Epilepsy Res."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2016.02.002","article-title":"Factors influencing topiramate clearance in adult patients with epilepsy: a population pharmacokinetic analysis","volume":"37","author":"Bae","year":"2016","journal-title":"Seizure"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/bmc.2726","article-title":"Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring","volume":"26","author":"Shibata","year":"2012","journal-title":"Biomed Chromatogr."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/psp4.12039","article-title":"Semi-mechanism-based population pharmacokinetic modeling of the Hedgehog pathway inhibitor vismodegib","volume":"4","author":"Lu","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejps.2013.07.008","article-title":"Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling","volume":"50","author":"Jovanovic","year":"2013","journal-title":"Eur J Pharm Sci."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.0013-9580.2005.55204.x","article-title":"Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine","volume":"46","author":"Britzi","year":"2005","journal-title":"Epilepsia"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00003088-199834050-00001","article-title":"Topiramate. Clinical profile in epilepsy","volume":"34","author":"Sachdeo","year":"1998","journal-title":"Clin Pharmacokinet."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.eplepsyres.2014.03.011","article-title":"Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment","volume":"108","author":"Manitpisitkul","year":"2014","journal-title":"Epilepsy Res."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e31827efe1d","article-title":"Factors influencing serum topiramate concentrations in routine therapeutic drug monitoring in Korean adult patients with epilepsy","volume":"35","author":"Huh","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/01.ftd.0000179847.37965.4e","article-title":"Pharmacokinetic variability of new antiepileptic drugs at different ages","volume":"27","author":"Perucca","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","article-title":"Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication","volume":"24","author":"May","year":"2002","journal-title":"Ther Drug Monit."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pediatrneurol.2004.04.005","article-title":"Age and antiepileptic drugs influence topiramate plasma levels in children","volume":"31","author":"Dahlin","year":"2004","journal-title":"Pediatr Neurol."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003088-200544040-00005","article-title":"Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data","volume":"44","author":"Battino","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201704000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:05:19Z","timestamp":1692050719000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201704000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000383","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}